drugset / Trial / NCT03030430

Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

NCT03030430

Phase 1 Completed 128 enrolled Bio-Thera Solutions
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to establish PK similarity in the treatment of BAT1706 and comparators.

Timeline

Start
2016-03-15
Primary completion
2017-05-16
Completion
2017-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject BAT1706 Unknown 1 mg/kg Intravenous
Comparator Bevacizumab Monoclonal antibody 1 mg/kg Intravenous